The next year, armodafinil, a related drug, was approved with a contraindication for children
with a contraindication following three months later for
modafinil. Contemporaneously, Cephalon agreed to pay $425 million for off-label marketing of modafinil. That means that for 18 months, the FDA kept quiet about the issue of SJS in children, while Cephalon continued off-label marketing at full steam.